EICHOR
● Recruiting
A Study of BGM0504 in Early T2DM With Obesity
Condition: Type 2 Diabetes (T2DM) · Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
About this study
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.
This description comes directly from the study's public registry record.
Talk to the study team
Zhu · +86025-68182432 · zhudalong@nju.edu.cn
Always discuss trial participation with your own doctor first.
Locations (1)
| Nanjing Drum Tower Hospital（The Affiliated Hospital of Nanjing University Medical School） | Nanjing, Jiangsu, China | Recruiting |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07743983